Efficacy of gabexate mesilate in preventing post endoscopic retrograde cholangiopancreatography pancreatitis: A meta-analysis of randomized clinical trials
| Autor: | Chun Chieh Chao, Yu Jui Chiu, Shao Chun Chen, Chun Chao Chang, Sen Kuang Hou, Yi No Kang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Abdominal pain Gabexate law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Endoscopic retrograde cholangiopancreatography law Internal medicine Pancreatitis prevention Humans Medicine Randomized Controlled Trials as Topic Cholangiopancreatography Endoscopic Retrograde lcsh:R5-920 FOY medicine.diagnostic_test business.industry Gabexate mesylate General Medicine Odds ratio medicine.disease Pancreatitis Protease inhibitor 030220 oncology & carcinogenesis Relative risk Meta-analysis Hyperamylasemia 030211 gastroenterology & hepatology medicine.symptom Somatostatin lcsh:Medicine (General) business |
| Zdroj: | Journal of the Formosan Medical Association, Vol 120, Iss 4, Pp 1090-1099 (2021) |
| ISSN: | 0929-6646 |
| Popis: | Background/purpose The evidence provided by syntheses of the preventative effects of gabexate mesilate against pancreatitis among patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) is limited and highly heterogeneous. To enhance the understanding of this topic, this study aimed to provide overview of gabexate mesilate on preventing post ERCP pancreatitis (PEP) by synthesizing all relevant randomized controlled trials (RCTs). Methods We searched three databases for relevant RCTs. Two authors independently extracted data of pancreatitis incidence after ERCP, abdominal pain within 48 hours, and hyperamylasemia for quality assessment and meta-analysis. Results Thirteen RCTs with 3718 patients undergoing ERCP met the eligibility criteria and were included. The results revealed that the use of gabexate mesilate led to lower PEP (Peto odds ratio: 0.66, 95% confidence interval [CI]: 0.49 to 0.89), especially in the subgroup of gabexate mesilate infusion starting more than 30 min (Risk ratio: 0.45, 95% CI: 0.29 to 0.72). Conclusion The present synthesis found that gabexate mesilate could be an option of prophylactic treatment of pancreatitis for patients undergoing ERCP, and reveals that it is favorable to administer it starting 30 min before the ERCP. This evidence may improve the clinical prevention of PEP. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|